MX2021015429A - Vesiculas extracelulares microbianas secretadas. - Google Patents

Vesiculas extracelulares microbianas secretadas.

Info

Publication number
MX2021015429A
MX2021015429A MX2021015429A MX2021015429A MX2021015429A MX 2021015429 A MX2021015429 A MX 2021015429A MX 2021015429 A MX2021015429 A MX 2021015429A MX 2021015429 A MX2021015429 A MX 2021015429A MX 2021015429 A MX2021015429 A MX 2021015429A
Authority
MX
Mexico
Prior art keywords
extracellular vesicles
microbial extracellular
secreted microbial
secreted
smevs
Prior art date
Application number
MX2021015429A
Other languages
English (en)
Spanish (es)
Inventor
Brian Goodman
Maria Sizova
Holly Ponichtera
Baundauna Bose
Andrea Itano
Alicia Ballok
Mark Bodmer
Sofia M R Carlton
Taylor A Cormack
Christopher J H Davitt
Loise Francisco-Anderson
Nihal Okan
Erin B Troy
Fabian B Romano-Chernac
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of MX2021015429A publication Critical patent/MX2021015429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021015429A 2019-06-11 2020-06-11 Vesiculas extracelulares microbianas secretadas. MX2021015429A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860049P 2019-06-11 2019-06-11
US201962860029P 2019-06-11 2019-06-11
US202062979545P 2020-02-21 2020-02-21
US202062991767P 2020-03-19 2020-03-19
PCT/US2020/037201 WO2020252144A1 (en) 2019-06-11 2020-06-11 Secreted microbial extracellular vesicles

Publications (1)

Publication Number Publication Date
MX2021015429A true MX2021015429A (es) 2022-01-24

Family

ID=71950732

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021015429A MX2021015429A (es) 2019-06-11 2020-06-11 Vesiculas extracelulares microbianas secretadas.
MX2021015427A MX2021015427A (es) 2019-06-11 2020-06-11 Vesiculas extracelulares microbianas procesadas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015427A MX2021015427A (es) 2019-06-11 2020-06-11 Vesiculas extracelulares microbianas procesadas.

Country Status (12)

Country Link
US (2) US20220249579A1 (enExample)
EP (2) EP3982987A1 (enExample)
JP (2) JP2022537684A (enExample)
KR (2) KR20220020893A (enExample)
CN (2) CN114096262A (enExample)
AU (2) AU2020291003A1 (enExample)
BR (2) BR112021024830A2 (enExample)
CA (2) CA3143036A1 (enExample)
CO (2) CO2022000040A2 (enExample)
MX (2) MX2021015429A (enExample)
TW (2) TW202114718A (enExample)
WO (2) WO2020252149A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090341B2 (en) * 2018-02-06 2021-08-17 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
KR102286042B1 (ko) * 2019-01-09 2021-08-03 주식회사 엠디헬스케어 데이노코커스 속 세균 유래 나노소포 및 이의 용도
JP7761556B2 (ja) * 2019-09-18 2025-10-28 リサーチ ディベロップメント ファウンデーション 代謝性疾患および障害を治療するための方法およびプロバイオティック組成物
TW202214276A (zh) * 2020-06-11 2022-04-16 美商艾弗洛生物科技股份有限公司 使用ｈａｒｒｙｆｌｉｎｔｉａ ａｃｅｔｉｓｐｏｒａ治療疾病和障礙之組成物及方法
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
AU2021296649A1 (en) * 2020-06-22 2023-02-09 Sl Bigen, Inc. Method and composition for enhancing cancer treatment efficacy of bacteria extracellular vesicles
CN116249540A (zh) * 2020-07-21 2023-06-09 伊夫罗生物科学公司 小韦荣氏球菌菌株作为神经炎性疾病的口服疗法
TW202227110A (zh) * 2020-09-21 2022-07-16 美商艾弗洛生物科技股份有限公司 用棲組織普雷沃菌調節免疫反應之組成物及方法
US20240423924A1 (en) * 2021-01-26 2024-12-26 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
WO2022178209A1 (en) * 2021-02-19 2022-08-25 Evelo Biosciences, Inc. Compositions and methods for treating metabolic diseases and disorders using christensenellaceae bacteria
WO2022221183A1 (en) * 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) * 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
CN117440819A (zh) * 2021-06-07 2024-01-23 Md保健株式会社 包含明串珠菌属细菌来源的囊泡的用于预防或治疗炎性疾病或癌症的组合物
WO2023114300A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114293A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
JP7856958B2 (ja) * 2023-05-22 2026-05-12 マイクロアルジェコーポレーション株式会社 免疫賦活用組成物及び発現誘導用組成物
CN118006515B (zh) * 2024-04-08 2024-06-18 中国农业大学 一株乳酸乳球菌及其在制备治疗牛乳腺炎的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102394638B1 (ko) * 2015-09-30 2022-05-09 (주)아모레퍼시픽 유산균 유래의 세포외 소낭을 포함하는 탈모 방지 또는 육모 촉진용 조성물
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
KR102563191B1 (ko) * 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
TW201920648A (zh) * 2017-08-29 2019-06-01 美商艾弗洛生物科技股份有限公司 使用布勞特氏(blautia)菌株治療癌症
AU2018330322A1 (en) * 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
BR112020004347A2 (pt) * 2017-09-08 2020-09-08 Evelo Biosciences, Inc. vesículas extracelulares de prevotella
CN111601610A (zh) * 2017-11-14 2020-08-28 伊夫罗生物科学公司 使用布劳特氏菌属菌株治疗疾病的组合物和方法
US11266700B2 (en) * 2017-11-15 2022-03-08 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains
CN109580960A (zh) * 2019-01-14 2019-04-05 周明 细胞外囊泡的分离方法、以及检测细胞外囊泡表面标志物的方法和试剂盒

Also Published As

Publication number Publication date
CN114650831A (zh) 2022-06-21
JP2022538765A (ja) 2022-09-06
JP2022537684A (ja) 2022-08-29
AU2020291003A1 (en) 2022-01-06
US20220249579A1 (en) 2022-08-11
EP3982986A1 (en) 2022-04-20
AU2020291434A1 (en) 2022-01-06
WO2020252144A1 (en) 2020-12-17
TW202114718A (zh) 2021-04-16
KR20220020894A (ko) 2022-02-21
CA3143036A1 (en) 2020-12-17
CA3143025A1 (en) 2020-12-17
MX2021015427A (es) 2022-01-24
WO2020252149A1 (en) 2020-12-17
BR112021024830A2 (pt) 2022-04-12
CN114096262A (zh) 2022-02-25
EP3982987A1 (en) 2022-04-20
TW202128198A (zh) 2021-08-01
BR112021024754A2 (pt) 2022-04-19
KR20220020893A (ko) 2022-02-21
CO2022000040A2 (es) 2022-01-17
US20220296654A1 (en) 2022-09-22
CO2022000041A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
MX2021015427A (es) Vesiculas extracelulares microbianas procesadas.
MX2020002659A (es) Vesiculas extracelulares bacterianas.
MX2020002660A (es) Vesiculas extracelulares de prevotella.
WO2020172492A3 (en) Bacterial membrane preparations
SA520412543B1 (ar) تركيبات وطرائق لعلاج السرطان والاضطرابات المناعية باستخدام جراثيم الفيونيلّة
SA520411910B1 (ar) تركيبات وطرق لعلاج اضطرابات مناعية باستخدام سلالات بكتيرية من المكورات اللبنية المعدلة للمناعة
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2018013995A (es) Células troncales mesenquimales y uso de las mismas para el tratamiento de lesiones musculares y enfermedades asociadas al músculo.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
MX2018006223A (es) Moduladores de ror-gamma.
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12016500024A1 (en) Bromodomain inhibitor
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
EP4233880A3 (en) Hnf4a sarna compositions and methods of use
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX392150B (es) Moduladores de receptores canabinoides.
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
WO2019178487A3 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2022015630A (es) Composiciones y metodos para el tratamiento de enfermedades y trastornos usando vesiculas extracelulares microbianas de oscillospiraceae.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
HK1246653A1 (zh) 奥那司酮延长释放组合物和方法
EA201692090A1 (ru) Полициклические активаторы herg